We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

Development of an In Vivo Non-Viral Ocular Editing Platform and Application to Potential Treatments for Glaucom ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

This study presents an optimized CRISPR-Cas12a system for large-scale genetic screening, revealing critical genes involved in lymphoma development and therapy.

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

Scientists have linked roughly five percent of adult cancers to mutations in genes called FOCAD and TTC37. Another gene known ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...